chevron_leftBack
As of 13 June 2026, SpyGlass Pharma, Inc. has a market cap of $735.38M USD, ranking #12608 globally and #2371 in the United States.
It ranks #1149 in the Healthcare sector, and #211 in the Biotechnology industry.
Key Stats
Market Cap
$735.38MUSD
Enterprise Value
$630.87MUSD
EBITDA (TTM)
-$40.84MUSD
Net Income (TTM)
-$39.87MUSD
PB Ratio
7.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Patrick Mooney
open_in_new
Employees
32
Founded
2019
IPO
06 Feb 2026
Website
spyglasspharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -4.4% | -10% | -2.7% | -31% | -27% | -27% |
News
Loading...
SGP Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SGP
ISIN: US85220G1094
Shares Out.:
Shares Outstanding:
33.433M1
Shares Float:
13.953M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
22.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which comprises novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
25K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
22K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
4K%
|
-
|
|
NYSE: IQV
|
$26.3B
3K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
3K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
2K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
6K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
6K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
6K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
6K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
4K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
3K%
|
-
|
chevron_leftBack